Conversely, all of them showed low toxicity in in vivo models, suggesting that inhibition of DDX3X activity per se is not toxic and that drugs with improved physicochemical and pharmacodynamic characteristics might represent a promising approach for breast cancer treatment. This evidence concerns the gene DDX3X and breast cancer.